Coherus Oncology, Inc. (CHRS) delivered a return of 92.81% over the past year. Since CHRS does not currently pay dividends, the total return equals the price-only return.

A $10,000 investment in Coherus Oncology, Inc. one year ago would be worth $19,281 today, representing a gain of $9,281.

Coherus Oncology, Inc. (CHRS) does not currently pay dividends. Many growth-focused companies reinvest profits back into the business rather than distributing them as dividends. For CHRS, the total return equals the price-only return.

Yes, Coherus Oncology, Inc. (CHRS) outperformed the S&P 500 by 67.82 percentage points over the past year. CHRS delivered a total return of 92.81%, compared to the S&P 500's 24.99%. This 67.82pp alpha means investors in CHRS earned more than a passive S&P 500 index fund.

Coherus Oncology, Inc. (CHRS) experienced a maximum drawdown of -45.82% over the past year, declining from its peak on 2026-01-27 to its trough on 2026-06-10. The stock has not yet fully recovered to its prior peak. Maximum drawdown measures the worst peak-to-trough decline and is an important risk metric for investors.

Here are Coherus Oncology, Inc. (CHRS)'s long-term returns with dividends reinvested. Over 10 years, the total return is -90.5% (-21.0% CAGR) — $10,000 would have grown to $947. Over 20 years: -88.3% total return (-10.2% CAGR) — $10,000 → $1,174. Over 30 years: -88.3% total return (-6.9% CAGR) — $10,000 → $1,174. Long-term investors benefit from compounding: dividends buy additional shares, which generate their own dividends, creating an exponential growth effect.

Coherus Oncology, Inc.'s best calendar year was 2019 with a total return of 97.4%. Its worst year was 2017 with a total return of -68.6%. This range shows the volatility investors should expect — the difference between the best and worst year is 166.0 percentage points.